Department of Pharmaceutical Services, Sanford University of South Dakota Medical Center, Sioux Falls, 57117-5039, USA.
Am J Health Syst Pharm. 2012 Jan 1;69(1):44-8. doi: 10.2146/ajhp110015.
The implementation of a pharmacist-led anticoagulation management service (AMS) and the clinical outcomes of inpatients receiving warfarin management are described.
An AMS was established at St. Mary's Medical Center (SMMC) in Duluth, Minnesota, in November 2003 at the request of orthopedic surgeons to manage warfarin for their patients postoperatively. The AMS was also available to other inpatients by physician request. All AMS pharmacists received didactic and experiential training. Each day, the managing pharmacist, usually the decentralized pharmacist, was responsible for checking the patients' International Normalized Ratio (INR); reviewing other pertinent laboratory test values, any medication changes, and vital signs; monitoring changes in the patients' clinical status, and writing an order for a warfarin dose. A database was created to help monitor patients managed by the AMS and to analyze monthly outcomes data. Clinical outcomes data were evaluated to identify areas of improvement for the AMS. All hospitalizations for patients who received anticoagulation therapy with warfarin managed by the AMS from January 1, 2006, through August 31, 2007, were analyzed. Primary endpoints, including thrombosis and bleeding complications during hospitalization, were identified for inclusion in the final hospital discharge data. Of the 2794 hospitalizations for patients managed by the AMS evaluated, 59 complications were identified. Of these, 14 (0.5%) were thrombosis events and 45 (1.6%) were bleeding events. INR results were also analyzed as secondary endpoints.
The evaluation of outcomes of the inpatient-based AMS at SMMC provided critical information to the anticoagulation subcommittee for consideration of quality-improvement efforts.
描述在药师主导的抗凝管理服务(AMS)实施前后,接受华法林管理的住院患者的临床结局。
明尼苏达州德卢斯的圣玛丽医疗中心(SMMC)应骨科医生的要求,于 2003 年 11 月设立了 AMS,以管理其术后患者的华法林治疗。其他有需要的住院患者也可以通过医生的要求使用 AMS。所有 AMS 药师都接受了理论和实践培训。每天,负责管理的药师(通常是分散的药师)负责检查患者的国际标准化比值(INR);审查其他相关的实验室检查值、任何药物变化和生命体征;监测患者临床状况的变化,并开具华法林剂量的医嘱。创建了一个数据库,以帮助监测由 AMS 管理的患者,并分析每月的结果数据。评估临床结果数据以确定 AMS 的改进领域。分析了 2006 年 1 月 1 日至 2007 年 8 月 31 日期间,接受 AMS 管理的华法林抗凝治疗的所有住院患者的临床结果数据。确定了主要终点,包括住院期间的血栓和出血并发症,以便纳入最终的出院数据。在评估的 2794 例由 AMS 管理的住院患者中,发现 59 例并发症。其中 14 例(0.5%)为血栓事件,45 例(1.6%)为出血事件。INR 结果也作为次要终点进行分析。
对 SMMC 基于住院患者的 AMS 的结果评估为抗凝小组委员会提供了关键信息,以供考虑进行质量改进工作。